TScan Guts 75% of Staff, Shelves Blood Cancer and Autoimmune Programs to Chase Solid Tumors
- TScan Therapeutics is pausing enrollment in its Phase 3 ALLOHA-2 trial of TSC-101, an allogeneic TCR-T therapy for blood cancers, citing insufficient funding to finish the study.
- The seven patients already dosed will keep being monitored; the company is now shopping the heme program to potential partners.
- TScan is also pausing its autoimmunity work, including its HLA-B*27 program in ankylosing spondylitis, while seeking outside partners for it as well.
- The company is cutting roughly 75% of its workforce and shutting down internal manufacturing to redirect resources toward its preclinical in vivo TCR-T platform for solid tumors.
- Management expects about $55 million in savings, pushing its cash runway out into Q4 2027.
Shelving a Phase 3 asset with seven patients already dosed — not a preclinical program — tells you where the real cash crunch sits. This isn't routine reprioritization; it's a company admitting it can't fund its most advanced bet to the finish line, however the release frames it. The pivot to in vivo TCR-T for solid tumors is bet-the-company: trading a derisked clinical program for an earlier-stage platform nobody has yet proven works in vivo. High conviction, but also a tacit admission the allogeneic heme franchise found no partner willing to bankroll it. Allogeneic TCR-T for blood cancers has gotten capital-intensive with thin differentiation between competitors — expect more heme/autoimmune cell-therapy assets to hit the partnering block as smaller players run short of runway before readouts. Reaching only Q4 2027 after cutting 75% of headcount suggests the burn problem was structural, not confined to the heme program.
TScan axes 75% of workforce to make room for solid tumor programs ↗